Cargando…

Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis

BACKGROUND: The most significant manifestation of heart failure is exercise intolerance. This systematic review and meta-analysis was performed to investigate whether dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide 1 receptor agonists (GLP-1 RAs), widely used anti-diabetic drugs,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chengcong, Huang, Ying, Zeng, Yongmei, Lu, Xiyan, Dong, Guoqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927173/ https://www.ncbi.nlm.nih.gov/pubmed/31870322 http://dx.doi.org/10.1186/s12872-019-01275-5

Ejemplares similares

Patients With Type 2 Diabetes Mellitus and Heart Failure Benefit More From Sodium-Glucose Cotransporter 2 Inhibitor: A Systematic Review and Meta-Analysis
por: Chen, Chengcong, et al.
Publicado: (2021)

CD14, CD163, and CCR1 are involved in heart and blood communication in ischemic cardiac diseases
por: Chen, Chengcong, et al.
Publicado: (2020)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

Dihydromyricetin Enhances Exercise-Induced GLP-1 Elevation through Stimulating cAMP and Inhibiting DPP-4
por: Wu, Luting, et al.
Publicado: (2022)

DPP4 gene variation affects GLP-1 secretion, insulin secretion, and glucose tolerance in humans with high body adiposity
por: Böhm, Anja, et al.
Publicado: (2017)

The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism
por: Pan, Xiaohui, et al.
Publicado: (2020)

Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
por: Gonzalez, Jimmy, et al.
Publicado: (2023)

The Effects of Aerobic Exercises and 25(OH) D Supplementation on GLP1 and DPP4 Level in Type II Diabetic Patients
por: Rahimi, Naser, et al.
Publicado: (2017)

Targeting cellular senescence prevents glucocorticoid-induced bone loss through modulation of the DPP4-GLP-1 axis
por: Wang, Tiantian, et al.
Publicado: (2021)

Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
por: Stenlid, Rasmus, et al.
Publicado: (2023)

Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective
por: Brown, Dominique Xavier, et al.
Publicado: (2012)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Noninvasive ventilation and exercise tolerance in heart failure: A systematic review and meta-analysis
por: Bündchen, Daiana C., et al.
Publicado: (2014)

Heart Failure Hospitalization with DPP-4 Inhibitors: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Singh, Awadhesh Kumar, et al.
Publicado: (2019)

From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy
por: Dicembrini, Ilaria, et al.
Publicado: (2011)

Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment
por: Sharma, Alok, et al.
Publicado: (2015)

The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
por: Nilsson, Malin, et al.
Publicado: (2019)

Saxagliptin Cardiotoxicity in Chronic Heart Failure: The Role of DPP4 in the Regulation of Neuropeptide Tone
por: Vörös, Imre, et al.
Publicado: (2022)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

Inhibition of DPP-IV Activity and Stimulation of GLP-1 Release by Gastrointestinally Digested Black Soldier Fly Prepupae
por: Luparelli, Anna Valentina, et al.
Publicado: (2023)

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
por: Złotek, Magdalena, et al.
Publicado: (2023)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2022)

The Effect of Carotid Chemoreceptor Inhibition on Exercise Tolerance in Chronic Heart Failure
por: Collins, Sophie É., et al.
Publicado: (2020)

Circulating dipeptidyl peptidase (cDPP3)—A marker for end‐stage heart failure?
por: Pavo, Noemi, et al.
Publicado: (2022)

Retraction Note: therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment
por: Sharma, Alok, et al.
Publicado: (2016)

Influence of Diet and Gender on Plasma DPP4 Activity and GLP-1 in Patients with Metabolic Syndrome: An Experimental Pilot Study
por: Pérez-Durillo, Francisco Tomás, et al.
Publicado: (2018)

DPP-4 inhibition enhanced renal tubular and myocardial GLP-1 receptor expression decreased in CKD with myocardial infarction
por: Kim, Seung Jung, et al.
Publicado: (2019)

A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes
por: Han, Eugene, et al.
Publicado: (2016)

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
por: Gilbert, Matthew P., et al.
Publicado: (2020)

Visceral adiposity, muscle composition, and exercise tolerance in heart failure with preserved ejection fraction
por: Ying, Wendy, et al.
Publicado: (2021)

Impact of Interatrial Shunts on Invasive Hemodynamics and Exercise Tolerance in Patients With Heart Failure
por: Griffin, Jan M., et al.
Publicado: (2020)

A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin
por: Balazki, Pavel, et al.
Publicado: (2020)

Effects of Sambiloto (Andrographis paniculata) on GLP-1 and DPP-4 Concentrations between Normal and Prediabetic Subjects: A Crossover Study
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2022)

The Impact of GLP-1 RAs and DPP-4is on Hospitalisation and Mortality in the COVID-19 Era: A Two-Year Observational Study
por: Greco, Salvatore, et al.
Publicado: (2023)

Analysis of Mutation Spectra of 28 Pathogenic Genes Associated With Congenital Hypothyroidism in the Chinese Han Population
por: Huang, Miao, et al.
Publicado: (2021)

Effect of optimized new Shengmai powder on exercise tolerance in rats with heart failure by regulating the ubiquitin-proteasome signaling pathway
por: Wang, Shuai, et al.
Publicado: (2023)

Heart rate recovery is useful for evaluating the recovery of exercise tolerance in patients with heart failure and atrial fibrillation
por: Tanaka, Seiya, et al.
Publicado: (2021)

Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Response to COVID-19 and diabetes: Can DPP4 inhibition play a role? – GLP-1 might play one too
por: Morin, Nathaniel
Publicado: (2020)

Attenuation of diabetic kidney injury in DPP4-deficient rats; role of GLP-1 on the suppression of AGE formation by inducing glyoxalase 1
por: Sarker, Mithun Kumer, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0f6bpt0vrblac1rrnpp9khsd7c